Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 116
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT06598332 | 5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD) | ||
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | ||
| NCT01109095 | CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM | ||
| NCT03690011 | Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells | ||
| NCT01853631 | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | ||
| NCT02291848 | Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma | ||
| NCT06198296 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | ||
| NCT02276820 | Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A) | ||
| NCT02239861 | TAA-Specific CTLS for Solid Tumors (TACTASOM) | ||
| NCT02905188 | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) | ||
| NCT00515957 | Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) | ||
| NCT01945619 | Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH) | ||
| NCT00578539 | T-Reg Cell Kinetics, Stem Cell Transplant, REGALE | ||
| NCT02932956 | Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) | ||
| NCT01316146 | Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) | ||
| NCT01611298 | Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR | ||
| NCT00902044 | Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma | ||
| NCT00078546 | EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) | ||
| NCT01189786 | Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection | ||
| NCT00058812 | Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts | ||
| NCT05134740 | (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). | ||
| NCT00062868 | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma | ||
| NCT04715191 | Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | ||
| NCT04377932 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | ||
| NCT01447056 | Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases | ||
| NCT02379520 | HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA | ||
| NCT00082225 | LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL) | ||
| NCT00953420 | Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes | ||
| NCT03081910 | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen | ||
| NCT01247701 | Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies | ||
| NCT04345601 | Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) | ||
| NCT00709033 | T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL | ||
| NCT01555892 | Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE | ||
| NCT06815432 | GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma | ||
| NCT00062855 | Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma | ||
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | ||
| NCT01494103 | Administration of Donor T Cells With the Caspase-9 Suicide Gene | ||
| NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors | ||
| NCT01247688 | Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies | ||
| NCT00224354 | Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells | ||
| NCT03768310 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | ||
| NCT00889954 | Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy | ||
| NCT00078533 | Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant | ||
| NCT00058617 | Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL | ||
| NCT00078520 | Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells | ||
| NCT00586274 | Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT | ||
| NCT03774654 | CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) | ||
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | ||
| NCT04099797 | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | ||
| NCT02442297 | T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors |
